Tech Company Financing Transactions
CytomX Therapeutics Funding Round
On 6/17/2015, CytomX Therapeutics raised $70 million in Series D funding from Fidelity Management & Research Company, Casdin Capital and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
6/17/2015
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds from the financing will support the continued advancement of CytomX's pipeline of Probody therapeutics toward clinical studies, including a Precision cancer immunotherapy directed against PD-L1 and Probody drug conjugates against novel, first in class targets. The financing will also support the expansion of Probody research and development activities in the areas of T-cell agonists, bispecific antibodies and engineered T-cell therapies.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 400
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
CytomX (NASDAQ: CTMX) is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean McCarthy
Chief Scientific Officer
Michael Kavanaugh
Vice President
Alison Joly
VP - Human Resources
Danielle Olander
VP - Manufacturing
Sridhar Viswanathan
Browse more venture capital transactions:
Prev: 6/17/2015: ServiceTitan venture capital transaction
Next: 6/17/2015: Mapbox venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs